What to Make of MannKind Earnings
Biotech company MannKind reported its first-quarter financial results after the markets closed Thursday.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 2654 Pharmaceutical Companies Leading the Breast Cancer Fight
In a new report, the RBC team focused on the companies that are making the most progress with treatments for patients with breast cancer.
Why These 4 Biotech Stocks Could Be the Next Buyout Targets
A new research note from SunTrust Robinson Humphrey mentions four stocks that they think could possibly get swept up in the biotech M&A excitement.
Is the PlasmaTech Bio Rally Sustainable?
Wednesday morning, PlasmaTech Bio announced that it has entered into a definitive agreement to acquire Abeona Therapeutics.
Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks
In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the right time to add biotech stocks.
Is Alexion Grossly Overpaying for Synageva?
Biotech giant Alexion Pharmaceuticals announced Wednesday morning that it will acquire Synageva BioPharma.
Top Credit Suisse Major Pharma Stock Picks to Buy
Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.
What Is Really Driving Array Higher
Array BioPharma released disappointing fiscal third-quarter earnings before the markets opened Monday morning.
2 Biotech Buyout Candidates as Antibiotics Stop Working
In a new report, the analysts at Stifel are very positive on two companies leading the charge against antibiotic-resistant "super bugs."
Can Immunomedics Double?
Immunomedics may be poised to make big moves going forward in 2015, according to Wells Fargo.
3 Biotech Stocks With Big Phase 3 Catalyst Data Due in 2015
Recently, biotech stocks have been getting stung pretty good, and now may be a good time to look at companies with pending catalysts.
Gilead Avoids the Earnings Hangman
Gilead Sciences reported better than expected first-quarter results Thursday after the markets closed.
How the Inovio Secondary Crushed Its Shareholders
A lot of times when companies have secondary offerings the price takes a slight dip to accommodate the dilution and price. However a landslide drop of almost 15% is not often in the cards.
Why These 2 Biotech Stocks May Be Bought Out Soon
In a new report, Stifel sees two biotech stocks with near-term catalysts that could make takeover candidates soon.
Is Celgene Stumped on Its Portfolio?
Celgene released mixed first-quarter results before the markets opened Thursday and shares were down in early trading.